GLYSET
Clinical safety rating
cautionComprehensive clinical and safety monograph for GLYSET (GLYSET).
Comprehensive clinical and safety monograph for GLYSET (GLYSET).
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Competitive inhibitor of alpha-glucosidase enzymes in the small intestine, delaying the breakdown of complex carbohydrates into monosaccharides and reducing postprandial hyperglycemia.
| Metabolism | Not metabolized; excreted unchanged primarily in feces (51% as unchanged drug, 35% as metabolites) and urine (2-5% as unchanged drug). |
| Excretion | Primarily excreted unchanged in the urine (renal elimination accounts for >95% of absorbed dose). Fecal elimination is negligible (<2%). |
| Half-life | Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function (creatinine clearance >60 mL/min). Clinical context: No accumulation occurs with twice-daily dosing in normal renal function; half-life is prolonged in renal impairment (up to 18 hours in end-stage renal disease). |
| Protein binding | Protein binding is very low (approximately 5-10%), primarily to albumin, with no significant binding to other plasma proteins. |
| Volume of Distribution | Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution mainly in extracellular fluid and minimal tissue binding. |
| Bioavailability | Oral bioavailability is <2% for the parent compound due to extensive metabolism by intestinal bacteria; however, the active metabolite (miglitol-like) has high local activity. Systemic absorption is minimal (1-2%), consistent with its site of action in the gut. |
| Onset of Action | Oral administration: Onset of action is within 1-2 hours, with peak effect on postprandial glucose reduction at approximately 1-2 hours after a meal. |
| Duration of Action | Duration of action is approximately 4-6 hours after a single oral dose, corresponding to the inhibition of intestinal alpha-glucosidases during carbohydrate digestion. Clinical note: The drug is administered with the first bite of each main meal to cover postprandial hyperglycemia. |
| Molecular Weight | 207.2 |
50 mg orally three times daily, titrated to 100 mg three times daily as tolerated, taken at the start of each meal.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if GFR < 25 mL/min/1.73 m². No adjustment needed for GFR ≥ 25 mL/min/1.73 m². |
| Liver impairment | No specific guidelines; use caution in Child-Pugh class B or C due to limited data. |
| Pediatric use | Not recommended for pediatric patients due to lack of safety and efficacy data. |
| Geriatric use | Initiate at lowest dose (50 mg three times daily); titrate cautiously due to age-related renal decline. |
| 1st trimester | Insufficient human data; animal studies show no teratogenic effects at clinically relevant doses. |
| 2nd trimester | Use only if clearly needed; no known fetal risk based on limited data. |
| 3rd trimester | Avoid during third trimester due to risk of neonatal hypoglycemia from maternal hyperinsulinemia. |
Clinical note
Comprehensive clinical and safety monograph for GLYSET (GLYSET).
| Placental transfer | Minimal; molecular weight >100 Da and low lipophilicity limit placental crossing. No specific studies confirm degree. |
| Breastfeeding | Miglitol is minimally excreted into breast milk; however, safety in nursing infants is not established. Use with caution, especially in preterm infants or those with gastrointestinal disorders. |
| Lactation Rating | L3 (Moderately safe) |
| Teratogenic Risk | Pregnancy Category B. No evidence of fetal harm in animal studies; no adequate human studies in first trimester. Use only if clearly needed. |
| Fetal Monitoring | Monitor blood glucose and HbA1c; assess for GI side effects; fetal ultrasound for growth if maternal diabetes poorly controlled. |
| Fertility Effects | No known adverse effects on fertility in animal studies; limited human data. |
■ FDA Black Box Warning
None
| Serious Effects |
Diabetic ketoacidosisInflammatory bowel diseaseColonic ulcerationPartial intestinal obstructionPredisposition to intestinal obstructionChronic intestinal diseases associated with marked disorders of digestion or absorptionConditions that may deteriorate as a result of increased gas formation in the intestineSevere renal impairment (CrCl <25 mL/min)Hypersensitivity to miglitol or any component
| Precautions | Hypoglycemia when used in combination with sulfonylureas or insulin (must be treated with glucose, not sucrose), Gastrointestinal adverse effects (abdominal pain, diarrhea, flatulence) due to undigested carbohydrates fermenting in the colon, Hepatotoxicity (rare, monitor liver enzymes), May cause loss of glycemic control if used with intestinal disorders |
| Food/Dietary | Avoid high-sucrose or fructose-containing foods and drinks as GLYSET inhibits the digestion of sucrose, leading to increased fermentation and gastrointestinal distress. Complex carbohydrates (starches) are affected; simple sugars like glucose are not. |
| Clinical Pearls | GLYSET (miglitol) is an alpha-glucosidase inhibitor that delays carbohydrate digestion, reducing postprandial hyperglycemia. It is not effective for fasting hyperglycemia and should not be used as monotherapy for type 1 diabetes or DKA. Monitor liver function tests; rare hepatotoxicity reported. Avoid in patients with inflammatory bowel disease or intestinal obstruction. |
| Patient Advice | Take with the first bite of each main meal to delay carbohydrate absorption. · Common side effects include flatulence, diarrhea, and abdominal discomfort, which often improve over time. · If hypoglycemia occurs, use glucose tablets or milk, not sucrose or fruit juice, as GLYSET prevents sucrose breakdown. · Monitor blood glucose regularly, especially when starting or changing dose. · Do not skip meals; take medication exactly as prescribed. |
Loading safety data…